Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anca Associated Vasculitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Anca Associated Vasculitis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-001663-33 Sponsor Protocol Number: MYCYC Start Date*: 2007-12-06
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis
    Medical condition: Anti neutrophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed) SE (Completed) DE (Completed) IT (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001222-15 Sponsor Protocol Number: CL002_168 Start Date*: 2011-07-20
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Bac...
    Medical condition: Non-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV) with mild-to-moderate renal involvement
    Disease: Version SOC Term Classification Code Term Level
    18.1 10047065 - Vascular disorders 10047115 Vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) SE (Completed) DE (Completed) NL (Completed) HU (Completed) PL (Completed) AT (Completed) IE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001970-28 Sponsor Protocol Number: CMV-001 Start Date*: 2012-11-20
    Sponsor Name:University of Birmingham
    Full Title: Does CMV reactivation cause functional impairment of CMV specific CD4+ T-cells? The potential for valaciclovir to prevent CMV-mediated adverse modulation of the immune system in patients with ANCA-...
    Medical condition: This study will investigate the modulation of the immune system by Cytomegalovirus (CMV) in ANCA-associated vasculitis. Specifically the study will investigate the potential for valaciclovir to ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    15.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-013220-24 Sponsor Protocol Number: Start Date*: 2009-11-02
    Sponsor Name:Addenbrooke's Hospital
    Full Title: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomised Controlled Trial
    Medical condition: ANCA associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    12 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) SE (Completed) DK (Completed) CZ (Completed) ES (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017087-17 Sponsor Protocol Number: AL1.0 Start Date*: 2010-09-29
    Sponsor Name:Addenbrooke's Hospital
    Full Title: Alemtuzumab for ANCA-Associated Refractory Vasculitis - A study of safety and efficacy (ALEVIATE).
    Medical condition: ANCA-associated vasculitis (AAV)
    Disease: Version SOC Term Classification Code Term Level
    12 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003588-69 Sponsor Protocol Number: W2018.034 Start Date*: 2019-03-07
    Sponsor Name:Leiden University Medical Center
    Full Title: The ENDURRANCE-1 Study. Exploring durable remission with rituximab in ANCA associated vasculitis
    Medical condition: ANCA associated vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003610-15 Sponsor Protocol Number: RITUXVAS Start Date*: 2005-12-15
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An international, randomised, open trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis.
    Medical condition: Anti neutophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001859-35 Sponsor Protocol Number: cro632 Start Date*: 2007-04-13
    Sponsor Name:Imperial College London
    Full Title: Abatacept in ANCA associated vasculitis: ABAVAS
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003964-30 Sponsor Protocol Number: BIOVAS Start Date*: 2020-10-22
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vascu...
    Medical condition: Non-ANCA associated vasculitides: 1. Giant cell arteritis (GCA) 2. Takayasu’s arteritis (TA) 3. Polyarteritis nodosa (PAN) or cutaneous polyarteritis unrelated to hepatitis B (CPAN) 4. Relapsing p...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10047115 Vasculitis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001121-14 Sponsor Protocol Number: CL010_168 Start Date*: Information not available in EudraCT
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculi...
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    20.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed) CZ (Completed) NL (Completed) ES (Completed) HU (Completed) DK (Completed) BE (Completed) NO (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003563-36 Sponsor Protocol Number: ACQUIVAS Start Date*: 2018-07-30
    Sponsor Name:Cambridge University Hospital NHS Foundation Trust and University of Cambridge
    Full Title: ACQUIVAS - Acquired immunodeficiency in ANCA associated vasculitis (AAV)
    Medical condition: Pneumococcal vaccine responses in ANCA associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-001102-14 Sponsor Protocol Number: Ritazarem Start Date*: Information not available in EudraCT
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis
    Medical condition: ANCA vasculitis.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10047065 - Vascular disorders 10047889 Wegeners granulomatosis LLT
    15.0 10047065 - Vascular disorders 10047888 Wegener's granulomatosis PT
    15.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    15.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed) SE (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004645-24 Sponsor Protocol Number: 206852 Start Date*: 2018-11-09
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: A randomized, double blind, controlled mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis
    Medical condition: ANCA-associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001807-29 Sponsor Protocol Number: 1508058 Start Date*: 2015-06-09
    Sponsor Name:CHU de Saint-Etienne
    Full Title: Pharmacokinetic study of rituximab induction regimen in ANCA-associated vasculitis : a predictive factor of clinical outcome? (MONITUX) - A multicentric study
    Medical condition: Granulomatosis with polyangiitis Microscopic polyangiitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    18.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004706-22 Sponsor Protocol Number: ImlifidARDSe.01 Start Date*: 2023-02-17
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Imlifidase in ANCA-associated vasculitis
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis with severe diffuse alveolar hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    21.1 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037314 Pulmonary alveolar hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001268-40 Sponsor Protocol Number: HAVEN Start Date*: 2020-01-23
    Sponsor Name:Guy's and St. Thomas' NHS Foundation Trust
    Full Title: Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial
    Medical condition: The term ANCA-associated vasculitis (AAV) describes a subset of primary small vessel vasculitides characterized by the presence of anti-neutrophil cytoplasmic antibodies (ANCA): Granulomatosis with...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-004138-26 Sponsor Protocol Number: ABAVAS Start Date*: 2007-11-04
    Sponsor Name:AZIENDA OSPEDALIERA DI PARMA
    Full Title: USE OF ABATACEPT IN ANCA-ASSOCIATED VASCULITIS
    Medical condition: Patients with ANCA-associated Vasculitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047888 Wegener's granulomatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003884-12 Sponsor Protocol Number: EXTRAStudy Start Date*: 2015-12-22
    Sponsor Name:AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII
    Full Title: A pilot, prospective, randomized, open-label, blinded endpoint (PROBE) histopathology trial to assess the effects of ACE- inhibition therapy on glomerular proliferative lesions in patients with ext...
    Medical condition: Extracapillary glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10018376 Glomerulonephritis proliferative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-000381-34 Sponsor Protocol Number: CL019_168 Start Date*: 2023-05-30
    Sponsor Name:ChemoCentryx
    Full Title: An Open Label, Randomized, Crossover, Single Dose Bioavailability Study in Healthy Adult Subjects to Evaluate the Pharmacokinetic Profile of an Exploratory Avacopan Pediatric Liquid Formulation Com...
    Medical condition: Anti-Neutrophil Cytoplasmic Antibody associated vasculitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-005535-24 Sponsor Protocol Number: ABROGATE-5527 Start Date*: 2016-06-07
    Sponsor Name:Univeristy of South Florida
    Full Title: Abatacept (CTLA4-Ig) for the treatment of relapsing, non-severe, granulomatosis with polyangiitis (Wegener's)
    Medical condition: Granulomatosis with polyangiitis (GPA; Wegener's granulomatosis)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10047889 Wegeners granulomatosis LLT
    19.0 100000004866 10047888 Wegener's granulomatosis LLT
    19.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:31:28 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA